Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised ...

Sonnet BioTherapeutics (SONN) announced positive findings from the first safety review of the expansion cohort in its Phase 1 SB101 clinical ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

Also Read: Amgen And Kyowa Kirin’s Rocatinlimab Reduces ... compared to 41.8% in the placebo group.1 No new safety signals were identified. The overall TEAE profile during the study period ...

ASP.NET Core is an open-source and cross-platform framework for building modern cloud-based internet-connected applications, such as web apps, IoT apps, and mobile backends. ASP.NET Core apps run on ...

She has 15+ years of experience as a financial writer and technical analyst. Michela Buttignol / Investopedia A net operating loss is when a business's expenses exceed its income, resulting in a ...

Amgen's operating income for Q4 was $2.311 billion. Their net income was $627 million. In 2025, Amgen expects revenues between $34.3B and $35.7B. The consensus is $34.53B. Here are some notable ...

Amgen (NASDAQ:AMGN) shares were on track for its seven straight sessions of gains on Monday, as the stock rose nearly 3% to $333.24 in afternoon trade. The biotechnology company gained over 5% in the ...

That doesn’t mean, however, that Amgen stock is ready for a reversal. It may, in fact, mean that the market views AMGN as a point of safety in the current storm of uncertainty. But AMGN is ...

Amgen and Kyowa Kirin’s anti-OX40 antibody rocatinlimab vindicated itself this weekend, with new Phase III data pointing to its strong efficacy in moderate to severe atopic dermatitis. These findings ...

Meanwhile, in pancreatic cancer, the company successfully cleared a critical safety review for its combination ... in LGSOC and a collaboration with Amgen to evaluate its therapy in combination ...

and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN ... double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every 4 weeks in 769 adults with ...